Literature DB >> 11516843

Is the alpha/beta ratio for prostate cancer low?

W D D'Souza, H D Thames.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11516843     DOI： 10.1016/s0360-3016(01)01650-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  19 in total

Review 1.  Radiation therapy dose escalation for prostate cancer: a rationale for IMRT.

Authors:  Alan Pollack; Alex Hanlon; Eric M Horwitz; Steven Feigenberg; Robert G Uzzo; Robert A Price
Journal:  World J Urol       Date:  2003-09-05       Impact factor: 4.226

2.  Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer.

Authors:  Jeffrey V Brower; Jeffrey D Forman; Patrick A Kupelian; Daniel G Petereit; Vinai Gondi; Colleen A Lawton; Nick Anger; Sandeep Saha; Rick Chappell; Mark A Ritter
Journal:  Radiother Oncol       Date:  2016-01-02       Impact factor: 6.280

3.  Early closure of phase II prospective study on acute and late tolerance of hypofractionated radiotherapy in low-risk prostate cancer patients.

Authors:  Katarzyna Behrendt; Elżbieta Nowicka; Marzena Gawkowska-Suwińska; Grzegorz Plewicki; Beata Smolska-Ciszewska; Monika Giglok; Rafał Suwiński; Aleksander Zajusz
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-15

4.  Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.

Authors:  Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-19       Impact factor: 7.038

5.  Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

Authors:  Thomas P Boike; Yair Lotan; L Chinsoo Cho; Jeffrey Brindle; Paul DeRose; Xian-Jin Xie; Jingsheng Yan; Ryan Foster; David Pistenmaa; Alida Perkins; Susan Cooley; Robert Timmerman
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

Review 6.  Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations.

Authors:  Nicholas J Sanfilippo; Benjamin T Cooper
Journal:  Am J Clin Exp Urol       Date:  2014-12-25

7.  Choline PET based dose-painting in prostate cancer--modelling of dose effects.

Authors:  Maximilian Niyazi; Peter Bartenstein; Claus Belka; Ute Ganswindt
Journal:  Radiat Oncol       Date:  2010-03-18       Impact factor: 3.481

8.  Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.

Authors:  Mark Ritter
Journal:  Semin Radiat Oncol       Date:  2008-10       Impact factor: 5.934

9.  Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer.

Authors:  Joseph C Hodges; Yair Lotan; Thomas P Boike; Rhonda Benton; Alyson Barrier; Robert D Timmerman
Journal:  J Oncol Pract       Date:  2012-05       Impact factor: 3.840

10.  Hypofractionation for prostate cancer.

Authors:  Mark Ritter; Jeffrey Forman; Patrick Kupelian; Colleen Lawton; Daniel Petereit
Journal:  Cancer J       Date:  2009 Jan-Feb       Impact factor: 3.360
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.